ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH DIFFUSE TOXIC GOITER AGAINST THE BACKGROUND OF DRUG THERAPY AND SURGICAL TREATMENT
Downloads
Objective: This study aims to evaluate the quality of life in patients with diffuse toxic goiter (DTG) undergoing drug therapy and surgical treatment. It also seeks to identify key predictors of complications associated with DTG. Methods: The study involved patients diagnosed with DTG, assessing the prevalence of subclinical and manifest thyrotoxicosis. The analysis focused on the impact of disease duration on complications such as thyrotoxic heart disease, endocrine ophthalmopathy, and toxic hepatitis. Additionally, the quality of life was compared between patients receiving thyroidectomy and those undergoing drug therapy with thyreostatics. Results: Findings indicate that DTG is more prevalent in women than men. Among the patients, subclinical thyrotoxicosis accounted for 66.7%, while manifest thyrotoxicosis was 33.3%. Disease duration was a critical factor in the progression of complications. Patients who underwent timely thyroidectomy exhibited better quality of life outcomes. Physical functioning improved by 23%, while emotional functioning, mental health, and social functioning increased by 40.7%, 22.5%, and 30.7%, respectively, compared to those receiving drug therapy. Novelty: This study highlights the significant role of thyroidectomy in improving the quality of life for DTG patients compared to drug therapy. It also emphasizes the predictive value of disease duration in the development of DTG-related complications, contributing to better clinical decision-making.
S. I. Ismailov, A. M. Akbutayev, M. M. Rashitov, and N. A. Alimdjanov, “Long-term outcome of total and subtotal thyroidectomy for Graves' disease in the Republic of Uzbekistan,” J. Theor. Clin. Med., no. 5, pp. 16–20, 2017.
A. S. Abdulkhalikov, “Modern possibilities of treatment of toxic goiter in the region of iodine endemia,” Clin. Med., no. 3, pp. 56–61, 2015.
B. H. Bebezov, M. A. Iuraliev, T. T. Kakchieeva, and B. E. Salieva, “Tactics of treatment of diffuse toxic goiter,” Clin. Med., vol. 91, no. 9, pp. 61–67, 2013.
G. A. Melnichenko, “Diffuse toxic goiter,” Rus. Med. J., vol. 11, no. 2, p. 79, 2003.
F. Menconi, C. Marcocci, and M. Marino, “Diagnosis and classification of Graves' disease,” Endocrinol. News Opin. Train., vol. 2, no. 7, pp. 41–48, 2014.
V. V. Fadeev, “On the materials of clinical recommendations of the American Thyroid Association on the diagnosis and treatment of thyrotoxicosis 2018,” Clin. Exp. Thyroidol., vol. 13, no. 3, pp. 45–56, 2017, doi: 10.14341/ket2017345-56.
D. A. Urunbayeva and D. T. Umarova, “Assessment of the quality of life of patients with diffuse toxic goiter against the background of drug therapy and surgical treatment,” Sci. J. Appl. Med. Sci., vol. 4, no. 1, pp. 101–109.
D. F. Schneider et al., “Thyroidectomy as primary treatment optimizes body mass index in patients with hyperthyroidism,” Ann. Surg. Oncol., vol. 21, no. 7, pp. 2303–2309, 2014.
T. J. Smith and L. Hegedus, “Graves' disease,” N. Engl. J. Med., vol. 375, no. 16, pp. 158–165, 2016.
G. Sjölin, “The long-term outcome of treatment for Graves' hyperthyroidism,” Thyroid, vol. 29, no. 11, pp. 1545–1557, Nov. 2019.
I. Tsymbaliuk, D. Unukovych, N. Shvets, and A. Dinets, “Cardiovascular complications secondary to Graves’ disease: A prospective study from Ukraine,” PLoS ONE, vol. 10, no. 3, 2015.
V. V. Fadeev, “Modern methods of determination of antibodies to the TSH receptor in the diagnosis and treatment of Graves' disease,” Clin. Exp. Thyroidol., vol. 9, no. 1, pp. 9–17, 2013.
A. S. Ametov, L. V. Kondratieva, and L. A. Bugova, “Graves' disease and functional autonomy of the thyroid gland in a region with mild iodine deficiency,” Clin. Exp. Thyroidol., vol. 7, no. 4, pp. 51–55, 2011.
M. M. Andreev, “Long-term results and quality of life of patients after surgical treatment of diffuse toxic goiter,” Postgrad. Bull. Volga Reg., no. 7–8, pp. 153–157, 2010.
S. I. Ismailov and S. U. Muminova, “The role of questionnaire in assessing the quality of life of patients with diabetes mellitus,” Int. Endocrinol. J., no. 2 (74), pp. 152–156, 2016.
A. V. Menkov, “Quality of life of patients after surgical treatment of benign thyroid diseases,” Med. Almanac., no. 4, pp. 117–120, 2012.
U. Z. Mirzaeva and H. R. Gulyamova, “Quality of life indicators of women with diffuse toxic goiter after treatment with radioactive iodine,” Clin. Thyroidol., vol. 14, no. 2, pp. 158–162, 2018, doi: 10.22141/2224-0721.14.2.2018.130561.
L. H. Kus, W. M. Hopman, I. J. Witterick, and J. L. Freeman, “Quality-of-life outcomes in Graves’ disease patients after total thyroidectomy,” Ear Nose Throat J., vol. 96, no. 4–5, pp. 8–15, 2017.
S. N. Styazhkina et al., “Evaluation of the quality of life of patients with diffuse toxic goiter after thyroidectomy,” Vol., vol. 9, no. 9 (1), pp. 26–30, 2019.
S. I. Ismailov and S. B. Rakhmanova, “Prediction of relapses after conservative therapy of Graves' disease,” Physician Postgrad., vol. 45, no. 2.4, pp. 601–606, 2011.
V. V. Fadeev, “Iododeficiency and autoimmune thyroid diseases in a region with mild iodine deficiency (epidemiology, diagnostics, treatment),” Doctoral dissertation, Moscow, 2004.
A. S. Abdulkhalikov, “Surgical treatment of recurrent thyrotoxicosis,” Med. Vestn. Sever. Kavkaza., vol. 23, no. 3, pp. 4–7, 2011.
V. E. Vanushko and V. V. Fadeev, “Graves' disease (clinical lecture),” Endocr. Surg., no. 1, pp. 23–33, 2013.
V. E. Vanushko and V. V. Fadeev, “Hypothyroidism as an outcome of surgical treatment of diffuse toxic goiter,” Sprav. Poliklin. Physician., no. 6, pp. 43–45, 2012.
I. A. Mirkhodjaev, “Evaluation of the effectiveness of surgical treatment of diffuse toxic goiter,” Electron. Sci. J. Biol. Integr. Med., no. 4, pp. 43–151, Apr. 2017.
E. A. Troshina, “Principles of thyreostatic therapy of Graves' disease (lecture),” Consilium Med., vol. 12, no. 12, pp. 64–68, 2012.
L. M. Farhutdinova and A. L. Bruyi, “Age peculiarities of diffuse toxic goiter: A case from practice,” Arch. Intern. Med., no. 3 (23), pp. 40–44, 2015.
L. Brammen, “Total thyroidectomy versus thionamides in patients with moderate-to-severe Graves' ophthalmopathy: A 1-year follow-up,” Trials, vol. 19, no. 1, p. 495, Sep. 2018, doi: 10.1186/s13063-018-2876-0.
S. I. Ismailov, N. A. Alimjanov, B. Kh. Babakhanov, M. M. Rashitov, and A. M. Akbutaev, “Long-term results after total thyroidectomy in patients with Graves’ disease in Uzbekistan: A retrospective study,” World J. Endocr. Surg., vol. 3, no. 2, pp. 79–82, May-Aug. 2011.
M. C. Shinall Jr. et al., “Total thyroidectomy for Graves' disease: Compliance with American Thyroid Association guidelines may not always be necessary,” Surgery, vol. 154, no. 5, pp. 1009–1015, 2013.
Copyright (c) 2025 Urunbayeva D.A, Umarova D.T, Bashirova A.E
This work is licensed under a Creative Commons Attribution 4.0 International License.
